MITSUBISHI TANABE PHARMA AMERICA

Name

MITSUBISHI TANABE PHARMA AMERICA

Legal name

TANABE PHARMA AMERICA, INC.

Website

https://mt-pharma-america.com

Company type

Private

Founded year

2016

Operating status

Operating

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Neurology / Rare Disease)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Neurodegenerative disease treatments
• Rare disease therapeutics
• Specialty pharmaceutical products
• Clinical stage pharmaceuticals
• Prescription drug development

Headquarters

HQ city

Jersey City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription pharmaceutical products including RADICAVA ORS (edaravone) for ALS treatment, with revenue generated through specialty pharmacy distribution and healthcare provider prescriptions.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Tanabe Pharma America develops and commercializes prescription pharmaceutical products for serious and debilitating diseases including ALS, Parkinson's disease, and rare disorders such as erythropoietic protoporphyria. Its commercial portfolio has centered on RADICAVA (edaravone) for ALS — available as an oral suspension (RADICAVA ORS) and previously as an IV formulation — while its investigational pipeline includes ND0612 subcutaneous infusion for Parkinson's disease, dersimelagon for EPP/XLP, and oncology and spinal cord injury assets.

Product overview

Tanabe Pharma America (formerly Mitsubishi Tanabe Pharma America) is a U.S. pharmaceutical company and wholly-owned subsidiary of Tanabe Pharma Corporation, focused on developing and commercializing treatments for serious and debilitating diseases. Its commercial portfolio historically centered on RADICAVA (edaravone), the first new FDA-approved ALS treatment in over two decades, available in both IV (RADICAVA IV, discontinued April 2025) and oral suspension (RADICAVA ORS) formulations. The company also commercialized EXSERVAN (riluzole) oral film for ALS, discontinued September 2024. The investigational pipeline includes ND0612 (24-hour subcutaneous levodopa/carbidopa infusion for Parkinson's disease, NDA under FDA review), dersimelagon/MT-7117 (selective MC1R agonist for EPP and XLP porphyrias, Phase 3 completed with positive results), MT-3921 (anti-RGMa monoclonal antibody for spinal cord injury), and MT-4561 (oncology, first patient dosed 2025). The RADICAVA business was transferred to Shionogi Inc. in April 2026. The company maintains patient support services including Searchlight Support and the JourneyMate nurse education program.

Differentiator

Problem solved

Functional benefit

Products and services

• RADICAVA ORS (edaravone oral suspension) FDA-approved oral suspension formulation of edaravone (105 mg/5 mL) for the treatment of amyotrophic lateral sclerosis (ALS). Taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial cycle, then 10 days within a 14-day period for subsequent cycles. Currently prescribed to more than 4,000 patients as of October 2024.
• ND0612 (continuous subcutaneous levodopa/carbidopa infusion) Investigational 24-hour continuous subcutaneous infusion of levodopa/carbidopa for Parkinson's disease. Developed by NeuroDerm, Ltd. Subject of the pivotal Phase 3 BouNDless trial and its open-label extension.
• Dersimelagon (MT-7117) Investigational novel synthetic, orally-administered, non-peptide small molecule selective melanocortin-1 receptor (MC1R) agonist in development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
• MT-3921 Investigational anti-RGMa (repulsive guidance molecule A) inhibition monoclonal antibody in development for spinal cord injury treatment, targeting a distinct pathophysiological pathway.
• MT-4561 Investigational oncology asset for advanced solid tumors; first patient dosed June 2025.
• Searchlight Support Patient support program offered by Tanabe Pharma America to assist patients and caregivers with access, reimbursement, and navigation support for the company's therapies.
• JourneyMate Program Live nurse educational phone support program for ALS patients and caregivers, part of the company's patient support ecosystem.

Quantifiable outcome

• 33% slowing of physical function loss in ALS patients vs placebo in pivotal Phase 3 trial
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core, strategic and minor.

• Shionogi Inc.coreStrategic or Co-development Partner · 22 December 2025Transfer of global rights to RADICAVA (edaravone) including rights in Japan, United States, and Canada to Shionogi. Transaction finalized April 1, 2026 to support long-term growth and sustainability of the brand.
• Dewpoint TherapeuticsstrategicStrategic or Co-development Partner · 17 December 2024Research collaboration between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to advance small molecule condensate modulator for ALS.
• Nobias TherapeuticsminorStrategic or Co-development Partner · 4 September 2024AI collaboration completed to further understanding of autism spectrum disorder.
• PANTHERxcoreChannel Partner/ Reseller/ Distributor · 25 June 2021Exclusive specialty pharmacy provider for EXSERVAN (riluzole oral film). Partnership ended with product discontinuation.
• ALS/MND Natural History Study ConsortiumstrategicStrategic or Co-development Partner · 3 March 2021Partnership to collect real-world data in ALS with the goal of improving patient care.
• Aquestive TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 21 January 2021Licensing and supply deal for riluzole oral film (EXSERVAN) using Aquestive's PharmFilm drug delivery technology. MTPA commercialized in U.S.; Aquestive served as exclusive sole manufacturer and supplier. Product discontinued September 2024.
• Oxford BiodynamicsminorStrategic or Co-development Partner · 3 May 2019Joined ALS biomarker study sponsored by Mitsubishi Tanabe Pharma America.
• Massachusetts General HospitalstrategicStrategic or Co-development Partner · 28 March 2019Collaboration on ALS biomarker study.
• Option CarecoreChannel Partner/ Reseller/ Distributor · 6 September 2017National home infusion services agreement for RADICAVA IV. Partnership ended with IV product discontinuation.
• ALS AssociationstrategicGTM or Marketing Partner · 20 September 2016National corporate sponsorship of Walk to Defeat ALS and care service programs. Partnership for ALS awareness, research funding, and advocacy efforts.
• NeuroDerm, Ltd.coreStrategic or Co-development PartnerNeuroDerm, Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation leading development of ND0612, a 24-hour continuous subcutaneous levodopa/carbidopa infusion for Parkinson's disease.
• United Porphyrias AssociationminorGTM or Marketing PartnerUPA provides recruitment information for INSPIRE clinical study of dersimelagon for EPP and XLP patients.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• UCB: UCB is a global biopharma with a strong neurology and rare disease portfolio (including epilepsy and myasthenia gravis treatments). They operate as a broad incumbent in the same neurology specialty channels and compete for the same specialist prescribers.
• Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharma with rare neurological disease products (including Xywav, Epidiolex). They share the specialty pharmacy distribution model and rare disease orphan drug commercialization playbook with Tanabe Pharma America.

Direct peers

• BioMarin Pharmaceutical: BioMarin is a rare disease specialty pharmaceutical company with multiple orphan drug products. Both companies focus on rare disease commercialization, orphan drug exclusivity strategies, and high-priced specialty therapeutics targeting limited patient populations.
• Amylyx Pharmaceuticals: Amylyx is a direct ALS competitor (maker of AMX0035/relyvrio, now discontinued but with follow-on pipeline). Both companies have ALS as a core indication and target the same specialist neurology prescribers with orphan drug pricing strategies.
• Supernus Pharmaceuticals: Supernus is a specialty pharma company focused on CNS disorders, with a similar profile of differentiated formulations of established molecules and a focus on neurology specialists. Both companies employ specialty pharmacy distribution and target rare neurology indications.
• Sage Therapeutics: Sage Therapeutics is a CNS-focused pharmaceutical company developing treatments for neurological disorders. They share the same late-stage clinical, regulatory, and commercialization playbook for CNS drugs targeting limited patient populations.
• Cytokinetics: Cytokinetics is a direct peer in ALS drug development (relyvrio was previously approved; their cardiac myosin activator is in development). Both companies target rare neuromuscular diseases with high unmet need and rely on specialist neurology channels and orphan drug pricing strategies.
• Recordati Rare Diseases: Recordati Rare Diseases is a specialty pharmaceutical company focused on rare disease treatments. Both companies share the orphan drug business model, specialty distribution approach, and focus on small patient populations with limited treatment options.
• Biogen: Biogen is the most direct peer — a major CNS/neurology pharmaceutical company with multiple ALS treatments (including Qalsody) and a strong Parkinson's disease and rare disease portfolio. Both companies compete in the U.S. neurology specialist prescriber market with similar HCP targeting and specialty pharmacy distribution models.

Emerging players

• Alnylam Pharmaceuticals: Alnylam is an emerging player in rare disease therapeutics with a strong pipeline of orphan drug products. Both companies target rare hereditary disorders with high unmet need and use orphan drug designation and premium pricing strategies.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TanabePharmaUS
• YouTubeyoutube.com/@TanabePharmaUS
• Facebookfacebook.com/TanabePharmaAmerica
• LinkedInlinkedin.com/company/tanabe-pharma-america

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MITSUBISHI TANABE PHARMA AMERICA